Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 123Carcinoma, Hepatocellular 72Neoplasms 48Breast Neoplasms 48Small Cell Lung Carcinoma 46Lung Neoplasms 42Triple Negative Breast Neoplasms 40Colorectal Neoplasms 39Melanoma 35Urinary Bladder Neoplasms 33Neoplasm Metastasis 31Carcinoma, Transitional Cell 31Carcinoma, Renal Cell 29Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 15Prostatic Neoplasms 13Liver Neoplasms 13Glioblastoma 12Solid Tumors 11Recurrence 11Sarcoma 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Lymphoma 9Endometrial Neoplasms 9Mesothelioma, Malignant 8Kidney Neoplasms 8

Interventions

Cisplatin 41Gemcitabine 25Fluorouracil 15Radiotherapy, Intensity-Modulated 14Radiotherapy 12Docetaxel 10pembrolizumab 8Paclitaxel 8Carboplatin 8Capecitabine 7Oxaliplatin 5toripalimab 4spartalizumab 4Bevacizumab 4camrelizumab 3Nivolumab 3Induction Chemotherapy 3Endostatins 3Cetuximab 3Acupuncture Therapy 3tislelizumab 2sintilimab 2nimotuzumab 2endostar protein 2apatinib 2Taxes 2Surveys and Questionnaires 2Polymerase Chain Reaction 2Nicotine 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nasopharyngeal Neoplasms × atezolizumab × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡